Related Experiment Videos
Celecoxib to decrease urinary retention associated with prostate brachytherapy
Steven J Feigenberg1, Kellie L Wolk, Chin-Huey Yang
1Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Purpose:
To retrospectively evaluate the effect of celecoxib in preventing urinary retention following prostate brachytherapy.
Materials And Methods:
Between December 1997 and November 2001, 149 patients underwent a prostate implant. Medical records were reviewed to identify those who had acute urinary retention after the procedure. Urinary retention was scored based on replacement of the urinary catheter and the number of calls to the clinic and/or unscheduled clinic visits within 1 month after the implant.
Results:
The use of celecoxib was associated with a decreased need for replacement of the catheter (p=.04) and decreased number of calls to the clinic and/or unscheduled clinic visits (p=.002). No patient who was given celecoxib for 1 week before brachytherapy required a urinary catheter compared to 14 (of 120) who did not receive celecoxib.
Conclusions:
The use of celecoxib appears to result in decreased urinary retention following prostate brachytherapy.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Urinary Tract Calculi III: Medical Management
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...